Interviews

Emily K. Curran, MD, addresses why patients with leukemia often need her more than their own primary care physician and what changes when they don’t.

Subcutaneous checkpoint inhibitors drove up volume and forced staffing changes, according to Angie Maynard, PharmD, MS, and bispecifics will bring another shift.

Kanita Bourne, LCSW, discusses how implicit bias, missed depression signs, and expanded doula access are shaping Black maternal health outcomes.

David Zhang, MD, discusses how real-world EHR and biobank data could advance polygenic risk scores for IPF diagnosis and risk prediction.

Swarup Kumar, MD, also details treating incarcerated patients with bispecifics and pursuing cure-focused therapy sequencing in myeloma.

Emily Curran, MD, University of Cincinnati, calls for decentralized trials and stronger community-academic ties to widen ALL patient access.

Deepak Bhatt, MD, MPH, MBA, discusses how new evidence, prevention definitions, and imaging advances are reshaping how PCSK9 and SGLT2 inhibitors are used.

INCA033989 showed responses across type 1 and type 2 mutant calreticulin-positive myelofibrosis, with phase 3 studies underway.

Deepak Bhatt, MD, MPH, MBA, discusses hot new topics reshaping care for diabetes, obesity, and cardiovascular disease.

Karilyn Larkin, MD, traces her equity focus to her medically underserved hometown, urging new diagnostics, trial design, and honest patient talks to close AML gaps.

Ajay K. Nooka, MD, MPH, explains why CD38 exposure complicates trial applicability, how MRD could speed approvals, and what a dex-free future looks like.

Robert Kratzke, MD, discusses how biomarker testing mandates and faster sequencing can improve access to precision lung cancer care.

INCA033989 showed encouraging spleen, anemia, and molecular responses in mutant calreticulin myelofibrosis, suggesting disease-modifying potential.

Stefanie Houseknecht, PharmD, discusses patient education, financial barriers, and pharmacy's expanding role in precision lung cancer care.

Jennifer Sheng, MD, discusses how consistent follow-up, patient education, and lifestyle interventions improve breast cancer survivorship care.

Financial toxicity in pediatric cancer extends beyond medical bills, affecting treatment adherence, caregivers, and survivors long-term, Cherie Daly, MD, said.

As presented at EHA 2026, AGAVE-201 showed no significant bone health safety signals with axatilimab in chronic graft-versus-host disease (cGVHD).

Ajai Chari, MD, addresses myeloma’s future: personalized care, shared decision-making, and why striving for a functional cure matters now.

Expanding on IVBM insights, Robert Kratzke, MD, discusses biomarkers, NGS panels, and treatment options for early-stage NSCLC without actionable alterations.

Kerry Rogers, MD, discusses financial toxicity, equitable access to BTK inhibitors, and how frailty shapes CLL clinical trial design.

Erin L. Duffy, PhD, MPH, discusses her findings that nonprofit and system-affiliated hospitals have better multilingual access to financial aid documents.

INCA033989 demonstrated spleen reductions, anemia responses, and molecular improvements in patients with mutant calreticulin–positive myelofibrosis.

The AGAVE-201 analysis found no significant bone health concerns with axatilimab in chronic GVHD, showing stable biomarkers and no increased fractures.

Robert Kratzke, MD, calls for a national biomarker testing mandate, emphasizing that timely genomic testing is essential for precision lung cancer care.

The Rutgers School of Public Health dean reflects on activism, apathy, and the road to treatment.

Tec-Dara showed higher MRD-negative CR rates and a 3-year PFS signal in high-risk relapsed/refractory MM, with durability still under longer-term follow-up.

Sarcoma's rarity and molecular diversity complicate trial design. Alexander Spira, MD, PhD, FACP, FASCO discusses biomarker testing, NGS panels, and referral gaps.

Minhee Kang, PharmD, discusses 3 key considerations for oncology pharmacists to improve treatment safety, patient education, and care delivery.